Regulatory/GMP Compliance

Jul 01, 2009
BioPharm International
The truth is, we should have been afraid of H1N1, because the threat of a flu pandemic is real.
Jul 01, 2009
BioPharm International
The introduction of two rival bills has intensified the long-simmering debate on biosimilars regulation in the US.
Jun 01, 2009
BioPharm International
Agency officials promise swift action against violators of drug safety and quality regulations.
May 01, 2009
BioPharm International
Authorities are pushing for CE; manufacturers prefer to focus on value.
May 01, 2009
BioPharm International
Avoiding healthcare reform is not the best option for the pharmaceutical industry.
Apr 01, 2009
BioPharm International
The 45 comments submitted raised concerns about legacy products and ongoing process monitoring.
Apr 01, 2009
BioPharm International
The FDA is poised to gain more authority and resources to ensure product quality.
Apr 01, 2009
BioPharm International
Follow a risk-based approach to maintain a state of control.
Mar 01, 2009
BioPharm International
Broader transparency in product prices and payments to researchers aim to curb conflicts of interest and rationalize drug expenditures.
Mar 01, 2009
BioPharm International
At some point, will heavy investments in large, stainless-steel based facilities become a burden to US companies?
native1_300x100
lorem ipsum